GlassScriptPhysician profile
Chelsae Castaneda
NPI 1245903426
$4,346.90
in general payments reported to CMS, 2019-2025
21 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $2,285 · 2023: $1,225 · 2024: $429 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $693.85 | 2021-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $595.32 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $572.74 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $506.34 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.07 | 2022-2024 | Caplyta |
| Ironshore Pharmaceuticals INC. | $341.34 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $330.11 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $252.40 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $95.55 | 2022-2024 | Trintellix |
| Janssen Scientific Affairs, LLC | $91.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $75.72 | 2022 | |
| Vanda Pharmaceuticals INC. | $73.06 | 2022-2023 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $60.13 | 2022-2023 | Aplenzin |
| Corium, LLC | $56.82 | 2022-2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $43.02 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $38.62 | 2024 | Xelstrym, Secuado |
| Indivior INC. | $31.86 | 2022 | |
| Neos Therapeutics, LP | $22.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.87 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $14.54 | 2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $12.97 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsae Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.